TargetMol

Levolansoprazole

Product Code:
 
TAR-T20714
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T20714-1mg1mg£297.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20714-5mg5mg£629.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20714-1mL1 mL * 10 mM (in DMSO)£780.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20714-10mg10mg£864.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20714-25mg25mg£1,251.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20714-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20714-100mg100mg£2,215.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Levolansoprazole, a proton pump inhibitor, irreversibly inhibits H+/K+-stimulated ATPase pumps in parietal cells (IC50: 5.2 μM). It also inhibits acid formation in isolated canine parietal cells (IC50: 82 μM). Both (R)- and (S)-lansoprazole are pharmacologically active with similar potencies.
CAS:
138530-95-7
Formula:
C16H14F3N3O2S
Molecular Weight:
369.36
Pathway:
Membrane transporter/Ion channel
Purity:
0.9862
SMILES:
Cc1c(C[S@@](c([nH]2)nc3c2cccc3)=O)nccc1OCC(F)(F)F
Target:
Proton pump

References

1. Gellad WF, Choi P, Mizah M, Good CB, Kesselheim AS. Assessing the chiral switch: approval and use of single-enantiomer drugs, 2001 to 2011. Am J Manag Care. 2014 Mar 1;20(3):e90-7. PubMed PMID: 24773330. 2. Cao Z, Chen Q, Zhang W, Liang X, Liao J, Liu W, Xiao S, Lu H. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial. Scand J Gastroenterol. 2015;50(10):1185-90. doi: 10.3109/00365521.2015.1037345. Epub 2015 Apr 16. PubMed PMID: 25881966.